Summary There is great concern over the long-term influence of oral contraceptives on the development of breast cancer in women. Oestrogens are known to stimulate the growth of human breast cancer cells, and this laboratory has previously reported (Jeng & Jordan, 1991) 
Millions of women benefit from oral contraceptives, a lowcost, low-toxicity, highly effective form of birth control. Studies assessing long-term risks associated with oral contraceptive use suggest that cancer risk of the endometrium (Salmi, 1979; Weiss & Sayvets 1980; Kaufman et al., 1980; Layde, 1982; Hulka et al., 1982) and the ovary (Layde, 1982; Newhouse it al., 1977; McGowan et al., 1979; Casagrande et al., 1979; Rosenberg et al., 1982) are decreased. The influence of oral contraceptives on the development of breast cancer remains controversial, with studies suggesting no effect (McPherson et al., 1983; Wiseman, 1983; Sattin et al., 1986; Buehring, 1988; Stadel, 1988; Schlesselman, 1989) or a slight increased effect on incidence (Pike et al., 1983; Olsson et al., 1985; Meirik et al., 1986; Longman & Buehring, 1987; McPherson et al., 1987 , Kay & Hannaford, 1988 Peto, 1989; Olsson et al., 1989) . In the United States, oral contraceptives have been used for 30 years, and therefore the influence of oral contraceptives on breast cancer may become apparent in the coming years as the first cohort of women to use oral contraceptives begin to enter menopause in large numbers.
Oestrogen is well known as an effective mitogen in the breast, but only recently has attention focused on the possible effects of the progestin as a potential stimulatory factor. Laboratory (Drill, 1977; Braunsberg et al., 1986; Haslam, 1988) and clinical (Pike et al., 1983; Henderson et al., 1988; Paul et al., 1989; Bergkvist et al., 1989; Anderson et al., 1989) data suggested a possible stimulatory role for progestins in breast cancer incidence. Other studies (Stoll, 1967; L0ber et al., 1981; Liang et al., 1983; Sutherland et at., 1988; Alexander et al., 1990; Abrams et al., 1990; Dauvois et al., 1990; Pap et al., 1991) appeared to refute progestin-mediated breast mitogenesis.
Our laboratory has approached this problem by developing a working hypothesis on progestin-mediated breast cancer cell proliferation. We suggest that the orally active progestational 1 9-nortestosterone derivatives are growth stimulatory in the breast. Our previous work (Jeng & Jordan, 1991) has shown that the 19-norprogestin norethindrone is effective in stimulating MCF-7 cell growth, and that this stimulation can be inhibited by the antioestrogen 4-hydroxytamoxifen.
In this study, we examined the 19-norprogestins norgestrel and gestodene to determine if these compounds also possessed oestrogen-like activity. All structures are shown in Figure 1 . Norgestrel is the sole hormonal agent in the subcutaneous contraceptive device NORPLANT* which is currently used by hundreds of thousands of women worldwide. Because of its convenience and effectiveness, NORPLANTJD may replace oral contraceptives as the most accepted means of contraception. Gestodene has proven to be a potent 19-norprogestin (Pollow et al., 1989) with a low incidence of side effects (Phillips, 1990 Colletta et al. (1991) suggests that the gestodene-induced growth inhibitory activity is mediated via TGF-P production. By contrast, our previous results (Jeng & Jordan, 1991) (Soule et al., 1973) were originally obtained from the Michigan Cancer Foundation. Cells were grown in minimal essential medium containing 5% (vol/vol) calf serum supplemented with 0.29 mg ml-' L-glutamine, 100 U ml-' penicillin plus 1I00 g ml-' streptomycin, 6 ng ml-' bovine insulin (Sigma Chemical Co., St which constitutively produces P-galactosidase, (MacGregor & Caskey, 1989 ) was used as a measure of transfection efficiency for all transfection studies. The imperfect palindrome (pS2ERE) was used in place of the vitERE in similar experiments. Cells were transfected with 10 ytg of reporter plasmid together with 5 fg of pCMV0 for 6 h and then treated with 10% glycerol in oestrogen free media for 3 min. Media containing various compounds were then added for 48 h. Cells were harvested and cytosol extracts were prepared by 3 cycles of freezing/thawing (liquid nitrogen/37°C). The activity of P-galactosidase in cytosol extracts was measured using 0-nitrophenyl P-D-galactopyranoside as the substrate. Aliquots of cytosol extracts containing equal amounts of P-galactosidase activity were used for the CAT assay in 150 ,lI reaction volumes containing 0.25 M Tris-HCI pH 7.5, 0.6 mM acetyl CoA (Sigma Chemical Co., St (b) PRE15-CAT assays MCF-7 cells that are oestrogen deprived possess a low progesterone receptor content. A low receptor content results in a very weak signal when using the transient transfection assay as described above. Therefore, an approach was necessary to boost progesterone receptor content. This problem was solved by supplementing the steroidfree media with 10-10M oestradiol. All other steps for transient were as described above, except that the PRE15-CAT plasmid construct was used.
Results

Norgestrel and gestodene influence on MCF-7 cell growth in vitro
The ability of oestradiol to stimulate proliferation of MCF-7 cells in vitro is well documented. We studied the influence of the compounds norgestrel, gestodene and MPA on the proliferation of MCF-7 cells relative to oestradiol stimulation. The results are depicted in Figure 2 . The control level represents the DNA content observed when no steroid was added. Oestradiol at 10-'3 M (0.27 pg ml-') is unable to stimulate cell proliferation beyond the control level, whereas an increase in concentration of 2 logs could stimulate maximal proliferation. Maximal Figure 2 The influence of oestradiol (0), norgestrel (@), gestodene (0), and MPA (O) in MCF-7 cell growth. The control level indicates the DNA level measured when cells were grown in the absence of steroid. Cells were seeded in 24 well plates at a density of 15,000 cells/well (in phenol minus minimal essential media with 5% stripped calf serum) and were deprived of oestrogen for 5 days. Compounds were then added at the concentrations indicated and media was changed every other day. After 6 days, the cells were disrupted and a 50 il cellular extract from each well was assayed for DNA content. Each concentration was done in triplicate. 164, 384 at all concentrations tested. Norgestrel was also not capable of stimulating cell proliferation above control levels in the presence of 10-6 M ICI 164, 384 (data not shown). Figure 5 The DNA sequence of the response elements used in this study. The vitERE is a perfect palindrome, while the pS2ERE has a single base pair change in this palindromic sequence, as well as a base pair change in the 3 bp spacer region. The PRE15 differs substantially from the various ERE sequences.
promotor, and finally the chloramphenicol acetyltransferase gene. Transient transfection with a vitERE-CAT plasmid construct provided a means of determining if norgestrel and gestodene were capable of activating the ERE. The results shown in Figure 5 indicate that oestradiol (at 10-10 M), norgestrel and gestodene (at 10-6M each) are capable of stimulating CAT activity above control levels, while MPA is unable to do so. The addition of the antioestrogen ICI 164, 384 dramatically inhibited the ability of oestradiol, norgestrel and gestodene to stimulate CAT activity (Figure 6 ).
Oestradiol, norgestrel and gestodene influence on pS2ERE-CA T activity Our next task was to examine whether the interaction was specific to the ERE palindromic sequence, or whether a nonspecific interaction within the plasmid was the cause of our results. In order to determine if the interaction with the ERE was specific, MCF-7 cells were transfected with pS2ERE-CAT, the nonperfect palindrome ERE-CAT plasmid construct ( Figure 5 ). This ERE has been shown to have lower affinity for the ER as compared to vitERE. Oestradiol, norgestrel and gestodene could only weakly stimulate CAT activity at concentrations that could stimulate strong CAT activity with the vitERE (Figure 7 ).
The ability of norgestrel, gestodene and oestradiol to regulate the expression ofprogesterone receptor message Progesterone receptor expression is known to be increased by oestradiol in MCF-7 cells (Ree et al., 1989) . The level of this protein can thus be used as a marker for successful oestrogen receptor activation. We examined the influence of norgestrel and gestodene on progesterone receptor levels (Figure 7) . At 10-8 M, neither gestodene nor norgestrel were able to stimulate production of progesterone receptor protein. Compounds tested Figure 7 The influence of oestradiol, gestodene, and norgestrel on pS2ERE-CAT activity. The protocol used is described in Figure 5 , with the exception that the pS2ERE-CAT plasmid was used rather than the vitERE-CAT. The control level represents pS2ERE-CAT activity in the absence of steroid. The open bars represent 10 -I°0M oestradiol, Ilo-6 IM gestodene, I 0-6IM norgestrel, respectively. The hatched bars represent these compounds (at the concentrations indicated) in the presence of ICI 164,384 at 10-6 M. The influence of MPA on CAT expression was weaker than all other compounds tested (data not shown).
ever, at 106 M, both compound could stimulate progesterone receptor production. MPA could not stimulate progesterone receptor levels at either of these concentrations.
PRE-CA T activity by oestradiol, norgestrel, gestodene and MPA with and without the antiprogestin RU486 Our results to this point suggested that the progestins acted as oestrogens in our model system. It was therefore important to show that the progestins could also interact with the progesterone receptor and induce transcription of genes located near a PRE ( Figure 5 ). However, progestin interaction with the progesterone receptor down-regulates receptor production (VuHai et al., 1978) , and at lower concentrations, the progestins did not provide an oestrogen-like stimulation of the progesterone receptor. As a result oestrogen was added to the medium to boost progesterone receptor production. We then transiently transfected a PRE15-CAT plasmid contruct into MCF-7 cells. Results shown on Figure 8 indicate that norgestrel and gestodene are capable of stimulating CAT activity at a lower concentration than the concentration capable of stimulating cell proliferation. MPA could stimulate PRE15-CAT activity despite an inability to stimulate cell proliferation (data not shown). The PRE15-CAT stimulation by norgestrel and gestodene could be blocked by the antiprogestin RU486, whereas RU486 could not block MCF-7 cell proliferation in the growth assays. Incidentally, without oestradiol boost, norgestrel and gestodene could still stimulate PRE-CAT expression in this system at 10-6 M (a concentration sufficiently oestrogenic to boost progesterone receptor (Table I) ), while MPA could not (data not shown).
Discussion
Our results demonstrate that the 19-nortestosterone derivatives norgestrel and gestodene stimulate MCF-7 cell (Iqbal et al., 1986 Markiewicz et al. (1992) . This stimulation occurs in a concentration dependent fashion, and can be inhibited by the pure antioestrogen ICI 164, 384. However, the finding that the antiprogestin RU486 is incapable of inhibiting progestin stimulated growth suggests that the growth stimulatory interaction is not mediated via the progestin receptor. This conclusion is supported by the inability of MPA to stimulate growth (Figure 1) or to stimulate vitERE-CAT activity ( Figure 5 ) while the capable of stimulating PRE15-CAT activity as much as 150% (data not shown).
Although norgestrel and gestodene are capable of stimulating PRE15-CAT activity at very low concentrations (Figure 8) , the progestational activity of these compounds do not appear to provide an attenuating effect of their oestrogen-like activity. The MCF-7 cell line proliferates in the presence of the progestin despite the presence of functional PR. We have also tested various 19-norprogestins in the T-47D cell line and have found similar stimulatory activity (unpublished observations). Based upon the correlation between the concentration of progestin required for vitERE-CAT activity and growth stimulation, it is likely that the growth stimulation is mediated via the oestrogen receptor rather than via the progesterone receptor.
The ability of norgestrel to provide effective birth control without the presence of an oestrogen (for example, the minipill and NORPLANT® formulations) had previously been inconsistent with our understanding of progestin biochemistry. If the progestin only acted through the progesterone receptor, the receptor should be downregulated and eventually result in the ineffectiveness of norgestrel. We suggest that norgestrel is also capable of interacting with the combined with 10-7M RU486. The transfection procedure was similar to that described in the caption for Figure 5 , except that the PRE1S-CAT plasmid construct was used and the progesterone receptor was boosted by adding oestradiol to the media.
oestrogen receptor, thus resulting in stimulation of progesterone receptor synthesis and maintained progestational activity.
It is noteworthy that the 19-norprogestins are capable of stimulating MCF-7 cell growth at concentrations as low as 10-M or 30 ng ml-'. Such concentrations are similar to plasma progestin concentrations seen in women who use oral contraceptives (Orme et al., 1983; Goldzieher, 1989) . Plasma progestin concentrations seen in NORPLANT® users (0.5 nl ml-' or approximately 10-10 M) are low enough to provide no growth stimulus above control in our model system (Croxatto et al., 1988; Shoupe & Mishell, 1989 , Shoupe et al., 1991 . Therefore, NORPLANT®D may offer advantages over the oral contraceptives by being effective at concentrations below those that stimulate breast cancer cell proliferation.
We suggest that the lowest effective concentration of 19-norprogestins should be pursued. Although developing lower dose formulations has been a priority for hormonal contraceptive manufacturers, our results indicate that the present progestin concentrations are still capable of stimulating human breast cancer. Furthermore, the assumption that progestin-only formulations are devoid of oestrogenic activity appears to be incorrect. For the present time, oral contraceptives should be measured by their total oestrogenicity (i.e. the oestrogen activity of oestrogen plus the oestrogenic activity of the progestin) in order to provide the most prudent and protective means of contraception. This oestrogenicity may also be determined for various formulations used in epidemiological studies that compare oral contraceptive use and breast cancer incidence, and may be one of the distinguishing characteristics betweens the conflicting results of these studies. 
